In 2007, the Food and Drugs Administration (FDA) requested that information about acute pancreatitis should be included in the product label for the GLP-1 receptor agonist, exenatide. This followed review of 30 post-marketing reports of pancreatitis in patients receiving this drug: in six patients symptoms had begun or worsened after a dose increase; twenty-one patients were admitted to hospital and in 22 cases symptoms improved after drug withdrawal. In three cases, symptoms recurred after exenatide was reintroduced. Another way of looking at the data would be to point out that 9/30 (30%) weren’t admitted to hospital and in only 17 cases (57%) was the serum amylase reported – not typical of a diagnosis of ‘pancreatitis’, in the UK at least. Most would also be very wary of ‘re-challenging’ their patients with a drug they felt was responsible for this serious condition.
Archives for March 2013
The Diabetes UK Professional Conference was hosted in the Manchester Central Convention Complex on 13-15 March 2013. With over 3,000 pre-registered delegates, there can be no doubt that Diabetes UK has found a successful formula for its annual get-together. However, it did lead me to compare and contrast with the last time its forerunner, the British Diabetic Association (BDA) held the Medical and Scientific Section Meeting in the same city.